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Abstract
Background: This study examined the pathophysiological abnormalities in Arab Americans with impaired fasting glucose
(IFG) and/or impaired glucose tolerance (IGT).
Subjects and Methods: Homeostasis model assessment of insulin resistance (HOMA-IR), homeostasis model assessment of
insulin secretion (HOMA-%b), and the Matsuda Insulin Sensitivity Index composite (ISIcomposite) were calculated from the
fasting and stimulated glucose and insulin concentrations measured during the oral glucose tolerance test in a population-
based, representative, cross-sectional sample of randomly selected Arab Americans.
Results: In total, 497 individuals (42 – 14 years old; 40% males; body mass index [BMI], 29– 6 kg/m2) were studied. Multi-
variate linear regression models were performed to compare HOMA-IR, HOMA-%b, and ISIcomposite among individuals with
normal glucose tolerance (NGT) (n = 191) versus isolated IFG (n = 136), isolated IGT (n = 22), combined IFG/IGT (n = 43), and
diabetes (n = 105). Compared with individuals with NGT (2.9 – 1.6), HOMA-IR progressively increased in individuals with
isolated IFG (4.8 – 2.7, P < 0.001), combined IFG/IGT (6.0 – 4.3, P < 0.001), and diabetes (9.7 – 8.3, P < 0.001) but not in those
with isolated IGT (3.0 – 1.7, P = 0.87). After adjustment for sex and BMI, these associations remained unchanged. Whole-body
insulin sensitivity as measured by ISIcomposite was significantly lower in individuals with isolated IFG (3.9 – 2.3, P < 0.001),
isolated IGT (2.8 – 1.5, P < 0.001), combined IFG/IGT (1.9 – 1.1, P < 0.001), and diabetes (1.6 – 1.1, P < 0.001) compared with
those with NGT (6.1 – 3.5). HOMA-%b was significantly lower in diabetes (113.7 – 124.9, P < 0.001) compared with NGT
(161.3 – 92.0). After adjustment for age, sex, and BMI, isolated IFG (146.6– 80.2) was also significantly associated with a
decline in HOMA-%b relative to NGT (P = 0.005).
Conclusions: This study suggests that differences in the underlying metabolic defects leading to diabetes in Arab Americans
with IFG and/or IGT exist and may require different strategies for the prevention of diabetes.
Introduction
Impaired fasting glucose (IFG) and impaired glucosetolerance (IGT) have been identified as independent pre-
cursors for the development of type 2 diabetes.1–3 Studies
have illustrated that different pathophysiological abnormali-
ties characterize isolated IFG and isolated IGT. Individuals
with isolated IFG have decreased hepatic insulin sensitivity
accompanied by reduction in basal and first-phase insulin
secretion.3–6 Those with isolated IGT have minimal reduction
in hepatic insulin sensitivity but instead have predominant
reduction in peripheral insulin sensitivity and reduced first-
and second-phase insulin secretion.3–5,7,8 In patients with
combined IFG/IGT, decreased hepatic/peripheral insulin
sensitivity and profound reduction in insulin secretion have
been documented.3,4,6
Emerging evidence also suggests that ethnic variation in
the natural history, etiology, and underlying pathology of IFG
and IGT exists.4,8–10 Abdul-Ghani et al.10 demonstrated dif-
ferences in the degree of insulin secretion and insulin sensi-
tivity among different ethnic populations with isolated IGT;
specifically, Arabs had a significantly greater reduction in
insulin secretion and lower reduction in insulin sensitivity
compared with Japanese and Mexican Americans. Decreased
insulin sensitivity was the predominant contributory factor to
the decline in b-cell function in Mexican Americans, whereas
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the decline in both insulin sensitivity and secretion influenced
conversion from normal glucose tolerance (NGT) to IGT in
Japanese subjects.10 In another study, a more significant im-
pairment in b-cell compensation for the degree of insulin
sensitivity was observed in Arab women with gestational
diabetes compared with Scandinavian women after adjust-
ment for body mass index (BMI).11
We have demonstrated that the prevalence of diabetes and
prediabetes is disproportionately high among Arab Ameri-
cans, posing a major public health burden.12 Greater insight
into the pathophysiological abnormalities leading to diabetes
in this population will facilitate the identification of phar-
macological strategies that may be used as early interventions
to prevent or delay the disease progression.13 Insulin sensi-
tivity and b-cell function have been examined in a small
number of Arabs with isolated IGT,10 but to date no studies
have described the transition in glucose homeostasis from
NGT to IFG, IGT, or combined IFG/IGT in this population. In
this analysis, we aim to compare the pathophysiological de-
fects of isolated IFG, isolated IGT, combined IFG/IGT, and
diabetes relative to NGT in a representative, cross-sectional
sample of Arab Americans. Preliminary results have been
presented elsewhere in abstract form.14
Subjects and Methods
The methods of this cross-sectional, population-based
study have been described in detail elsewhere.12 In brief, an
initial sampling frame of households was constructed in two
geographical areas of Dearborn, MI, that are predominantly
inhabited by Arab Americans. Nonpregnant adults 20–75
years of age with native Arab ancestry were randomly se-
lected from these sampling frames. Arab Americans were
defined by self-report of Arab ancestry of the individual, a
parent, or a grandparent. The study was approved by the
Wayne State University Institutional Review Board. All par-
ticipants provided written informed consent.
Eligible individuals reported to the clinic following a 12-h
overnight fast. Standardized questionnaires translated into
Arabic were used to assess demographic factors. Height and
body weight were measured in light clothing and without
shoes. BMI was calculated as the body weight (in kilograms)
divided by the square of the height (in meters).
Fasting blood samples were collected for measurement of
plasma glucose and serum insulin and lipid concentrations.
Individuals without documented diabetes underwent a 75-g
oral glucose tolerance test (OGTT), and blood samples were
collected at 120min for measurement of plasma glucose and
serum insulin levels. Plasma glucose concentrations were
measured by an automated glucose oxidase method using
Behring Diagnostics (La Jolla, CA) reagents (SVR glucose
test). The serum insulin level was measured with a double
antibody radioimmunoassay (Linco Research, St. Charles,
MO) and was standardized against the International Re-
ference Preparation (National Institute for Biological Stan-
dards and Control, Potters Bar, Hertfordshire, United
Kingdom). Total cholesterol and triglyceride concentrations
were measured using enzymatic colorimetric techniques
(Cobas Mira Chemstation; Roche, Indianapolis, IN). High-
density lipoprotein cholesterol was measured with a high-
density lipoprotein direct assay using the elimination
approach and meeting the National Cholesterol Education
Program guidelines for precision and accuracy (Cobas Mira
Chemstation). Low-density lipoprotein cholesterol was cal-
culated using the equation of Friedewald et al.15
Individuals were considered to have diabetes if they re-
ported a previous medical diagnosis of diabetes and/or were
using insulin or oral antihyperglycemic agents. Glucose tol-
erance status of individuals without a previous diagnosis of
diabetes was defined according to the 2012 American Dia-
betes Association OGTT-based diagnostic criteria.16
Insulin resistance was estimated using the homeostasis
model assessment (HOMA) of insulin resistance (HOMA-IR)
and was defined as (fasting serum insulin [in lU/mL] ·
fasting plasma glucose [in mmol/L])/22.5.17 Insulin secretion
was calculated using the homeostasis model assessment of b-
cell function (HOMA-%b) and was calculated as (fasting se-
rum insulin [in lU/mL] · 20)]/(FPG [in mmol/L] – 3.5).17
Insulin sensitivity was also measured using the Matsuda
Insulin Sensitivity Index composite (ISIcomposite), calculated as
[k/O(G0 · I0 ·G120 · I120)], where k (= 10,000) is the constant,
G0 and G120 are the plasma glucose concentrations at times 0
and 120min, respectively, and I0 and I120 are the plasma in-
sulin concentrations at times 0 and 120min, respectively.18
Descriptive statistics were performed to compare the de-
mographic characteristics of participants by glucose tolerance
status. Data are expressed as mean– SD values or percent-
ages. Depending on whether the outcome measure was con-
tinuous or categorical, data were analyzed using analysis of
variance or v2 test, respectively. Multivariate linear regression
models for HOMA-IR, HOMA-%b, and ISIcomposite were built
with backward selection with a removal threshold of P = 0.2
with linear age, linear BMI, and sex considered as covariates.
Analyses were completed using the statistical software
package STATA version 11.0 (StataCorp, College Station, TX).
A two-tailed P < 0.05 was considered statistically significant.
Results
In total, 542 Arab Americans participated in this study. Of
these, 45 individuals without a history of diabetes did not
have complete OGTT data and were excluded from this
analysis, for a final study sample of 497. Demographic char-
acteristics are presented in Table 1. Males accounted for 40%
of the study population. The mean age was 42 – 14 years. The
mean BMI was 29 – 6 kg/m2. Isolated IFG, isolated IGT,
combined IFG/IGT, and diabetes were present in 27%, 4%,
9%, and 21% of the participants, respectively.
Mean – SD age was significantly higher in individuals with
isolated IFG (39 – 12 years), isolated IGT (45 – 14 years), and
those with combined IFG/IGT (46– 16 years) compared with
those with NGT (37– 12 years). Compared with NGT, there
was a significantly higher percentage of men with isolated
IFG (P < 0.001) but a smaller percentage with isolated
IGT (P = 0.03) and combined IFG/IGT (P = 0.007). BMI was
significantly higher in individuals with isolated IFG
(29.4 – 5.4 kg/m2 vs. 27.3 – 5.8 kg/m2, P = 0.001) and those
with combined IFG/IGT (30.0 – 4.7 kg/m2 vs. 27.3 – 5.8 kg/
m2, P = 0.005) but not in those with isolated IGT (29.1 – 4.9 kg/
m2 vs. 27.3 – 5.8 kg/m2, P = 0.18) relative to NGT. Relative to
individuals with NGT, those with combined IFG/IGT had
significantly higher total cholesterol, low-density lipoprotein
cholesterol, and triglyceride concentrations (all comparisons
P = 0.003). In contrast, high-density lipoprotein cholesterol
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concentrations were significantly lower in those with isolated
IFG, isolated IGT, and combined IFG/IGT compared with
those with NGT (all comparisons P < 0.05). Fasting insulin
concentrations were significantly higher in individuals with
isolated IFG (P < 0.001) and those with combined IFG/IGT
(P < 0.001) but not in those with isolated IGT (P = 0.61) relative
to NGT. Individuals with isolated IFG, isolated IGT, and
combined IFG/IGT had significantly higher postprandial in-
sulin concentrations compared with those with NGT (all
comparisons P < 0.001).
As shown in Table 1, there were few differences in demo-
graphic characteristics between those with isolated IFG, iso-
lated IGT, and combined IFG/IGT. Individuals with isolated
IGT were older and had higher postprandial insulin concen-
trations but significantly lower fasting insulin concentrations
relative to those with isolated IFG. Age, total cholesterol, and
fasting and postprandial insulin concentrations were higher
in individuals with combined IFG/IGT compared with those
with isolated IFG. Individuals with combined IFG/IGT also
had significantly higher fasting insulin concentrations relative
to those with isolated IGT.
Measures of HOMA-IR, HOMA-%b, and ISIcomposite are
presented in Table 2. Compared with individuals with NGT
(2.9 – 1.6), themean ( – SD)HOMA-IR progressively increased
in individuals with isolated IFG (4.8 – 2.7, P < 0.001), com-
bined IFG/IGT (6.0 – 4.3, P < 0.001), and diabetes (9.7 – 8.3,
P < 0.001) but not in thosewith isolated IGT (3.0 – 1.7,P = 0.87).
After adjustment for sex, and BMI, these associations re-
mained unchanged. Additionally, HOMA-IR was signifi-
cantly higher in individuals with isolated IFG compared with
those with isolated IGT (P = 0.002) and with combined IFG/
IGT versus both isolated IFG (P = 0.025) and isolated IGT
(P = 0.003).
Whole-body insulin sensitivitymeasuredwith the ISIcomposite
was significantly lower in individuals with isolated IFG
(3.9 – 2.3, P < 0.001), isolated IGT (2.8 – 1.5, P < 0.001), com-
bined IFG/IGT (1.9 – 1.1, P < 0.001), and diabetes (1.6 – 1.1,
P < 0.001) relative to those with NGT (6.1 – 3.5). After adjust-
ment for sex, and BMI, these associations remained un-
changed. Furthermore, insulin sensitivity was significantly
lower with isolated IGT relative to isolated IFG (P= 0.010) and
with combined IFG/IGT versus both isolated IFG (P < 0.001)
and isolated IGT (P = 0.013).
Compared with NGT (161.3 – 92.0), HOMA-%b was sig-
nificantly decreased with the onset of diabetes (113.7 – 124.9,
P < 0.001). After adjustment for age, sex, and BMI, IFG was
also significantly associated with a decline in HOMA-%b
relative to NGT (P = 0.005). HOMA-%b was significantly
lower in individuals with isolated IFG compared with those
with isolated IGT (P = 0.021) and combined IFG/IGT
(P = 0.029). There were no differences noted between com-
bined IFG/IGT versus isolated IGT (P = 0.63).
Discussion
This study was conducted to examine potential differences
in the pathophysiologic mechanisms of insulin resistance or
sensitivity and insulin secretion across the spectrum of glu-
cose intolerance in a population-based random sample of
Arab Americans. Insulin sensitivity as measured by the ad-
justed HOMA-IR was significantly lower with isolated IFG
versus isolated IGT and in combined IFG/IGT versus isolated
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IFG and isolated IGT. On the other hand, insulin sensitivity as
measured by the adjusted ISIcomposite was significantly lower
with isolated IGT versus isolated IFG and in combined IFG/
IGT versus isolated IFG and isolated IGT. Adjusted HOMA-
%b was significantly lower with isolated IFG versus isolated
IGT and combined IFG/IGT.
Our findings are consistent with several but not all studies
that used the HOMA method for estimation of insulin resis-
tance. Several studies have suggested that differences in
HOMA-IR between the glucose intolerance states exist; insu-
lin sensitivity is significantly decreased in individuals with
isolated IFG and combined IFG/IGT.3,4,19–21 Isolated IGT
usingHOMA-IRwas also associatedwith a significant decline
in insulin sensitivity in some but not all studies.3–5,19–22 In
addition to HOMA measurements, the insulin sensitivity in-
dex has been widely used to describe the pathophysiologic
mechanisms of glucose intolerance. The ISIcomposite, which
estimates whole-body insulin sensitivity using two sample
points for plasma glucose and insulin measurements, has
been shown to be comparable to insulin sensitivity measures
using five sample points.18 A study of 1,264 Asian Indians has
reported significant differences in NGT versus both isolated
IFG and isolated IGT as calculated using HOMA-IR and sig-
nificant differences in NGT versus isolated IFG, isolated IGT,
combined IFG/IGT, and diabetes as calculated using the
modified Matsuda index.23 Using the Matsuda ISIcomposite in
our population, we have demonstrated significant differences
in all categories of glucose intolerance compared with NGT
and when comparing isolated IFG versus isolated IGT and
combined IFG/IGT versus isolated IFG and isolated IGT.
Several studies have described a significant decline in b-cell
function in individuals with isolated IFG, isolated IGT, and
combined IFG/IGT.3,4,19,20,22 Studies assessing insulin secre-
tion using HOMA-%b resulted in findings similar to those
reported in this study with respect to comparisons among
isolated IFG, isolated IGT, and combined IFG/IGT.5,20,22
There are several potential limitations to our study. First, we
used the HOMAmethod for estimating insulin resistance and
secretion in this population-based randomly selected sample
of ArabAmericans. Although this method has been correlated
to the hyperinsulinemic–euglycemic clamp, fasting glucose
levels significantly influence the accuracy of HOMA estima-
tion indices.4,24 In addition, the indices in the formula do not
account for potential variations in insulin clearance. Second,
postprandial insulin concentrations were derived from a
single OGTT testing, limiting our ability to assess the hyper-
bolic relation between insulin secretion to insulin sensitivity in
individuals with isolated IFG, isolated IGT, and combined
IFG/IGT.25 Third, IFG was the most prevalent abnormality
followed by diabetes in our population. Using the current
American Diabetes Association criteria, the prevalence of IFG
of 27% shown here is 19% higher than the rate we previously
reported, stemming from a disproportionately high number
of individuals with isolated IFG compared with those with
isolated IGT or combined IFG/IGT.12,16 It is plausible that the
lack of significant changes in HOMA-%b shown here in in-
dividualswith isolated IGT or combined IFG/IGTmay in part
be due to the small sample size of these groups. Fourth, there
are multiple factors that can influence insulin resistance such
as waist-hip ratio, hypertension, hypertriglyceridemia, low
high-density lipoprotein cholesterol, C-peptide, hemoglobin
A1C, and fasting insulinemia that could not be systematically
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assessed. Finally, the cross-sectional design of our study
limited the ability to assess the natural progression of these
metabolic abnormalities across the disease continuum.
In conclusion, given the high prevalence of prediabetes
and diabetes in the Arab American population, a clear un-
derstanding of the underlying pathophysiological mecha-
nisms of the glucose intolerance states leading to diabetes is
important. This study suggests that differences in the meta-
bolic defects in Arab Americans with IFG and/or IGT may
exist andmay require different strategies for the prevention of
diabetes. It appears that interventions that encompass en-
hancing insulin sensitivity and preserving b-cell functionmay
be more efficacious for preventing diabetes in this vulnerable
population.
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